Cardiogen
Ala-Glu-Asp-Arg / AEDR peptide
Cardiogen is a synthetic tetrapeptide (Ala-Glu-Asp-Arg) developed by Professor Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology, designed as a bioregulator peptide specific to cardiac tissue. It is theorized to normalize gene expression in cardiomyocytes by penetrating cell nuclei and interacting with DNA regulatory sequences. Research applications focus on cardiac tissue repair, prevention of age-related myocardial deterioration, and post-ischemic cardioprotection.
Mecanismo de Acción
Synthetic tetrapeptide bioregulator that targets cardiac tissue. Promotes cardiomyocyte differentiation, enhances cardiac stem cell activity, and may improve myocardial function by modulating gene expression in heart tissue. Part of the Khavinson bioregulator class.
Protocolos de Investigación
Para propósitos de investigación solo. No es asesoramiento médico.
Research protocols (Khavinson method) use 10-20mg orally or sublingually daily for 10-30 day cycles. Sublingual preferred. Cycles repeated every 3-6 months.
Notas de Investigación
Clinical Research Status
Cardiogen has been investigated in clinical studies conducted primarily in Russia, with reports of improved cardiac function markers in elderly patients with age-related cardiovascular deterioration. Studies have examined its use both as a standalone intervention and in combination with other bioregulator peptides as part of comprehensive anti-aging protocols. It is available as a supplement in Russia but has not been evaluated by Western regulatory agencies or subjected to large-scale randomized controlled trials meeting international standards.
Key Published Findings
Research demonstrates that Cardiogen can stimulate proliferation and differentiation of cardiac stem cells in vitro, potentially contributing to myocardial regeneration. Animal studies show reduced infarct size and improved left ventricular function when administered following experimental myocardial ischemia. Gene expression analysis indicates upregulation of cardioprotective factors including heat shock proteins and anti-apoptotic genes in cardiomyocyte cultures exposed to Cardiogen.
Safety Profile
Available literature reports no adverse effects from Cardiogen administration at recommended doses, consistent with the general safety profile of ultrashort bioregulator peptides. Its constituent amino acids (alanine, glutamic acid, aspartic acid, arginine) are all naturally occurring and rapidly metabolized through normal physiological pathways. No contraindications have been formally established, though patients with active cardiac conditions should not use investigational peptides as substitutes for established medical treatments.
Comparison to Related Compounds
Cardiogen is tissue-specific to cardiac muscle, while the related Khavinson peptide Vessels (Lys-Glu-Asp-Trp) targets vascular endothelium, and Thymalin addresses immune function. Unlike BPC-157, which provides general tissue healing through angiogenesis and growth factor modulation, Cardiogen is theorized to work through direct gene regulatory mechanisms specific to cardiomyocytes. Compared to pharmaceutical cardioprotective agents like trimetazidine, Cardiogen represents a fundamentally different approach through peptide bioregulation rather than metabolic modulation.
Community Observations
Users in longevity-focused communities often incorporate Cardiogen as part of broader Khavinson peptide stacks targeting multiple organ systems simultaneously. Reported benefits are generally subtle and difficult to verify without echocardiographic or biomarker monitoring, making subjective assessment challenging. The peptide is typically used in 10-30 day cycles several times per year, following protocols established in Russian gerontological practice.
Media Vida
~15-30 minutes
Reconstitución
N/A (typically oral/sublingual capsule)
Almacenamiento
Liofilizado
Room temperature. Protect from moisture.
Reconstituído
N/A (oral form)
Estado Legal EE.UU.
También Se Conoce Como
Preguntas frecuentes
¿Qué es Cardiogen?
Cardiogen is a synthetic tetrapeptide (Ala-Glu-Asp-Arg) developed by Professor Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology, designed as a bioregulator peptide specific to cardiac tissue. It is theorized to normalize gene expression in cardiomyocytes by penetrating cell nuclei and interacting with DNA regulatory sequences. Research applications focus on cardiac tissue repair, prevention of age-related myocardial deterioration, and post-ischemic cardioprotection.
¿Cómo funciona Cardiogen?
Synthetic tetrapeptide bioregulator that targets cardiac tissue. Promotes cardiomyocyte differentiation, enhances cardiac stem cell activity, and may improve myocardial function by modulating gene expression in heart tissue. Part of the Khavinson bioregulator class.
¿Cuál es el estado regulatorio de Cardiogen en EE. UU.?
Research chemical (not FDA-approved)
¿Cuál es la vida media de Cardiogen?
~15-30 minutes
¿Qué otros nombres tiene Cardiogen?
Ala-Glu-Asp-Arg, AEDR peptide
Peptide Contacts proporciona resúmenes basados en investigaciones únicamente para fines informativos. No hospedamos, distribuimos ni endosamos la documentación del proveedor. Todos los certificados de análisis, certificados GMP y comunicaciones del proveedor deben solicitarse y verificar directamente por el comprador. Nada en esta plataforma constituye asesoramiento legal, médico o profesional. Los usuarios son únicamente responsables de verificar las credenciales del proveedor y asegurarse de cumplir con todas las leyes locales, estatales y federales aplicables antes de comprar cualquier químico de investigación. El uso de esta plataforma constituye aceptación de toda la responsabilidad personal.
Leer aviso completo